Short answer
Syndax Pharmaceuticals Inc (SNDX) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $46M (up 267.0% year over year) with net income of −$61M.
Q3 2025 key financials · XBRL
- Revenue
- $46M
- +267.0% YoY · +21.6% QoQ
- Net income
- −$61M
- +27.8% YoY · +15.5% QoQ
- Operating margin
- -125.2%
- EPS (diluted)
- −$0.69
- +29.6% YoY · +17.9% QoQ
Source: XBRL data from the Syndax Pharmaceuticals Inc (SNDX) Q3 2025 10-Q on SEC EDGAR. USD.
Syndax Pharmaceuticals Inc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: ongoing U.S. government shutdown since Oct 1, 2025 may delay FDA's review of regulatory submissions, material adverse effect possible
- Updated competition risk: FDA approved Imbruvica, Rezurock, Jakafi for cGVHD, challenging Niktimvo’s market adoption and limiting commercial scope
- Legal/compliance risk: off-label promotion risks FDA enforcement and potential violations of the Federal Food, Drug, and Cosmetic Act and FCA statutes
- Operational risk: adverse drug side effects like differentiation syndrome and QTc prolongation in Revuforj label could delay trials or restrict label use
- No new financial risk detailed; prior liquidity or concentration risks appear unchanged since last 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Syndax Pharmaceuticals Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.